Will Key Drugs Maintain Momentum for Novartis in Q2 Earnings?

Novartis AG (NVS) is scheduled to report Q2 2025 earnings on July 17, with consensus estimates at $14.04 billion in revenue and $2.38 EPS. Despite a consistent track record of beating estimates, Zacks' model does not conclusively predict an earnings beat for this quarter due to a negative Earnings ESP. Expected growth drivers include strong sales momentum from key drugs such as Entresto, Kisqali, Kesimpta, and Pluvicto, the latter benefiting from recent FDA approval. Strategically, Novartis recently acquired Regulus Therapeutics for $0.8 billion, enhancing its pipeline, while its shares have significantly outperformed the industry, gaining 27.3% year-to-date.

Analysis

Novartis is approaching its Q2 2025 earnings report with significant underlying operational strength, although quantitative models suggest uncertainty regarding an earnings beat. The company's growth is expected to be propelled by a portfolio of high-performing drugs, including Entresto, Kisqali, and Kesimpta, with consensus sales estimates for the quarter pegged at $2.3 billion, $1 billion, and $1 billion, respectively. The recent FDA approval for Pluvicto, which has tripled its eligible patient population, and strong uptake of Scemblix are also key catalysts. This positive momentum, however, is partially offset by anticipated generic competition for older products like Tasigna and Lucentis. Strategically, the company has sharpened its focus on core therapeutic areas following the Sandoz spin-off and is actively bolstering its pipeline, evidenced by the $0.8 billion acquisition of Regulus Therapeutics. Despite a strong history of beating earnings estimates by an average of 7.12% over the last four quarters, the current negative Earnings ESP of -0.28% tempers expectations for another surprise. Given that NVS shares have already rallied 27.3% year-to-date, significantly outpacing the industry's 1.8% growth, current market valuation appears to have priced in much of this operational success.

Key Decisions for Investors

• Given the robust sales momentum in key drugs and the strategic pipeline enhancement via the Regulus acquisition, investors with a long-term fundamental view may see the current situation as supportive of a core holding.
• Caution is warranted for the short-term around the July 17th earnings release, as the negative Earnings ESP (-0.28%) combined with the stock's 27.3% year-to-date rally creates a risk of a pullback if results do not meet elevated expectations.
• Investors should scrutinize the reported sales figures for growth drivers like Entresto, Kisqali, and Pluvicto against their consensus estimates, as well as management's guidance on the impact of generic competition, to gauge the sustainability of the company's growth trajectory.